NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Clinical Trials
9 trialsNCT03643744 2024-12-19
Photodynamic Therapy-Induced Immune Modulation: Part III
Wright State University
Phase 1 Terminated
NCT02054104 2022-01-26
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01313429 2020-03-03
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01341496 2018-07-05
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00027976 2013-08-05
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
University of Alabama at Birmingham
Phase 2/3 Withdrawn
NCT00023621 2013-06-26
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025051 2013-03-22
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00197912 2010-04-26
Dendritic Cell Based Therapy of Malignant Melanoma
Herlev Hospital
Phase 1/2 Completed